Patient reported outcomes in subjects with type 2 diabetes treated with monotherapy regimens of once-daily human GLP-1 analogue liraglutide or glimepiride

被引：0
|
作者：
Bode, B. W. [1 ]
Hale, P. M. [2 ]
Hammer, M. [3 ]
Testa, M. A. [4 ]
Garber, A. [5 ]
机构：
[1] Atlanta Diabet Associates, Atlanta, GA USA
[2] Novo Nordisk Inc, Princeton, NJ USA
[3] Novo Nordisk AS, DK-2880 Bagsvaerd, Denmark
[4] Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA
[5] Baylor Coll Med, Houston, TX 77030 USA
来源：
DIABETOLOGIA | 2008年 / 51卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
894
引用
收藏
页码：S357 / S358
页数：2
相关论文
共 50 条
  • [41] Liraglutide, a once-daily human GLP-1 analogue, reduces the prevalence of prediabetes in obese subjects over 20 weeks: a randomized placebo-controlled trial
    Finer, N.
    Al Hakim, M.
    Astrup, A.
    Harper, A.
    Lean, M.
    Niskanen, L.
    Rasmussen, M. F.
    Rissanen, A.
    Rossner, S.
    Van Gaal, L.
    DIABETOLOGIA, 2009, 52 : S11 - S12
  • [42] The once-daily human glucagon-like peptide-1 (GLP-1) analog liraglutide improves postprandial glucose levels in type 2 diabetes patients
    Anne Flint
    Christoph Kapitza
    Charlotte Hindsberger
    Milan Zdravkovic
    Advances in Therapy, 2011, 28 : 213 - 226
  • [43] The Once-Daily Human Glucagon-Like Peptide-1 (GLP-1) Analog Liraglutide Improves Postprandial Glucose Levels in Type 2 Diabetes Patients
    Flint, Anne
    Kapitza, Christoph
    Hindsberger, Charlotte
    Zdravkovic, Milan
    ADVANCES IN THERAPY, 2011, 28 (03) : 213 - 226
  • [44] Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide
    Astrup, A.
    Carraro, R.
    Finer, N.
    Harper, A.
    Kunesova, M.
    Lean, M. E. J.
    Niskanen, L.
    Rasmussen, M. F.
    Rissanen, A.
    Rossner, S.
    Savolainen, M. J.
    Van Gaal, L.
    INTERNATIONAL JOURNAL OF OBESITY, 2012, 36 (06) : 843 - 854
  • [45] Liraglutide, a human GLP-1 analogue, reduces bodyweight in subjects with type 2 diabetes, irrespective of body mass index at baseline
    Schmitz, O.
    Russell-Jones, D.
    Shaw, J.
    Brandle, M.
    Matthews, D.
    Frid, A.
    Zdravkovic, M.
    Garber, A.
    Zinman, B.
    DIABETOLOGIA, 2008, 51 : S354 - S355
  • [46] Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide
    A Astrup
    R Carraro
    N Finer
    A Harper
    M Kunesova
    M E J Lean
    L Niskanen
    M F Rasmussen
    A Rissanen
    S Rössner
    M J Savolainen
    L Van Gaal
    International Journal of Obesity, 2012, 36 : 843 - 854
  • [47] Beneficial effect of the GLP-1 analogue liraglutide on blood pressure and cardiovascular biomarkers in subjects with Type 2 diabetes
    Vilsboell, T.
    Zdravkovic, M.
    Le-Thi, T.
    Krarup, T.
    Schmitz, O.
    Courreges, J.
    Verhoeven, R.
    Buganova, I.
    Madsbad, S.
    DIABETIC MEDICINE, 2007, 24 : 3 - 3
  • [48] A meta-analysis of six clinical trials demonstrates that the once-daily human GLP-1 analogue liraglutide reduces systolic blood pressure
    Fonseca, V.
    Falahati, A.
    Zychma, M.
    Madsbad, S.
    Plutzky, J.
    DIABETOLOGIA, 2009, 52 : S299 - S299
  • [49] Liraglutide, a once-daily human GLP-1 analogue, improves pancreatic B-cell function and arginine-stimulated insulin secretion during hyperglycaemia in patients with Type 2 diabetes mellitus
    Vilsboll, T.
    Brock, B.
    Perrild, H.
    Levin, K.
    Lervang, H. -H.
    Kolendorf, K.
    Krarup, T.
    Schmitz, O.
    Zdravkovic, M.
    Le-Thi, T.
    Madsbad, S.
    DIABETIC MEDICINE, 2008, 25 (02) : 152 - 156
  • [50] The once-daily human GLP-1 analogue liraglutide increases the beta cell mass in normoglycaemic mice by directly accelerating cell differentiation and proliferation
    Shimoda, M.
    DIABETOLOGIA, 2009, 52 : S34 - S35
12345